4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
NCT ID: NCT03578354
Last Updated: 2024-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2019-01-31
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine
NCT02350985
Chinese Real-world Study of Treatment of Vestibular Migraine
NCT07203248
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
NCT04353505
Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine
NCT02615314
Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine
NCT01807234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4-AP
15 mg 4-aminopyridine twice daily
4-aminopyridine
an oral drug to be swallowed
Atenolol
25 mg atenolol twice daily
Atenolol
an oral drug to be swallowed
Placebo
Masked placebo twice daily
Placebo
a masked placebo to be swallowed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
4-aminopyridine
an oral drug to be swallowed
Atenolol
an oral drug to be swallowed
Placebo
a masked placebo to be swallowed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Psychiatric illness requiring medication
* Medical illness including cancer, coronary artery or cerebrovascular disease
* Known allergy to one of the test medications
* Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures
* Taking migraine prophylactic medication or vestibular suppressants.
* Pregnant or breast feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts Eye and Ear Infirmary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard Lewis
Associate Professor, Otolaryngology and Neurology; Director, Jenks Vestibular Laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pending
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.